

## **OTC Pink Basic Disclosure Guidelines - 2014 & 2015 Annual Reports**

### **1) Name of the issuer and its predecessors (if any)**

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

TULIP BIOMED, INC.

### **2) Address of the issuer's principal executive offices**

#### Company Headquarters

Address 1: 2885 Sanford Ave SW 34538

Address 2: Grandville, MI 49418

Address 3: \_\_\_\_\_

Phone: (866) 804-4725

Email: hamogroup1@gmail.com

Website(s): http://www.bitcoinservices.biz/

#### IR Contact

Address 1: NONE

Address 2: \_\_\_\_\_

Address 3: \_\_\_\_\_

Phone: \_\_\_\_\_

Email: \_\_\_\_\_

Website(s): \_\_\_\_\_

### **3) Security Information**

Trading Symbol: TPBM

Exact title and class of securities outstanding: COMMON

CUSIP: 899296 20 6

Par or Stated Value: \$0.001

Total shares authorized: 500,000,000. as of: 2/03/2016

Total shares outstanding: 69,567,051. as of: 2/03/2016

Common shares are entitled to one vote per share.

Additional class of securities (if necessary):

Trading Symbol: NONE

Exact title and class of securities outstanding: Series "A" Preferred

CUSIP: NONE

Par or Stated Value: \$0.001

Total shares authorized: 100,000,000. as of: 2/03/2016

Total shares outstanding: 5,366,666. as of: 2/03/2016

Shares of Series "A" Preferred Stock enjoy dividend and liquidation preferences, are entitled to vote, and are convertible into one share of Common Stock at an exercise price of \$.001 per share at the earlier to occur of (i) a firmly underwritten public offering covering the primary sale of Common Stock, (ii) a vote or written consent of holders of at least a simple majority of the Series "A" Preferred Stock then outstanding, voting as a class, or (iii) December 31, 2006.

Additional class of securities (if necessary):

Trading Symbol: NONE

Exact title and class of securities outstanding: Series "B" Convertible Preferred

CUSIP: NONE

Par or Stated Value: \$0.001

Total shares authorized: 20,000,000. as of: 2/03/2016

OTC Markets Group Inc.

OTC Pink Basic Disclosure Guidelines (v1.1 April 25, 2013)

Page 1 of 7

Total shares outstanding: 9,390,362. as of: 2/03/2016

Shares of Series "B" Preferred Stock are convertible into one share of Common Stock only at the express authorization of the Company to convert.

Transfer Agent

Name: Signature Stock Transfer, Inc.

Address 1: 2632 Coachlight Court

Address 2: Plano, Texas 75093

Address 3: \_\_\_\_\_

Phone: 972.612.4120

Is the Transfer Agent registered under the Exchange Act?\* Yes: X No: ☐

\*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

No stock splits or stock dividends are anticipated or have occurred in the past 12 months. On December 15, 2015, District Court Judge in Clark County, Nevada issued an order of appointment of custodianship to Hamo Enterprises, Inc. Since that time, the custodian has complied with the Court's Order and reinstated the corporate charter and business license, filed statutory disclosures to amend the articles of incorporation with the Nevada Department of Corporations, and now files this OTC Markets disclosure statement with new business operations to further the interests of the shareholders.

**4) Issuance History**

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

On January 11, 2016, for consideration of certain advancements of funds and services rendered to the Company, the Company issued Hamo Enterprises, Inc. fifty million common shares, five million series a preferred and five million series b preferred shares. All of these shares are restricted and control person shares.

On January 31, 2016, pursuant to agreement, the Company issued one hundred and fifty thousand (150,000) restricted shares of the common stock to the principal - Sanjay Aurora of Finance & Technology Consultants, Inc. for accounting services rendered in preparation of the 2014 & 2015 Annual Reports for the Company.

On January 31, 2016, pursuant to agreement, the Company issued Two Million and Five Hundred (2,500,000.) restricted shares of the common stock and paid \$2,500. to TST Advisors LLC, for content management, E-Commerce Solutions, affiliate Consulting, Third party payment options, Analytics, Search Engine Optimization, Custom WordPress Development, Custom Web Development, custom logo design, custom landing pages, custom web site design, web development, social networks, web site consulting, corporate identity package, web site management, and web site hosting services.

B. Any jurisdictions where the offering was registered or qualified;

None

C. The number of shares offered;

None

D. The number of shares sold;

None

E. The price at which the shares were offered, and the amount actually paid to the issuer;

None

F. The trading status of the shares; and

Restricted/Control Person as noted above.

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Yes, Restricted/Control Person as noted above.

## **5) Financial Statements**

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

- A. Balance sheet;
- B. Statement of income;
- C. Statement of cash flows;
- D. Financial notes; and
- E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otcq.com in the field below.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

## **6) Describe the Issuer's Business, Products and Services**

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

The issuer's business operations are each Internet based to the consumer and consist of three separate streams, as follows: (1) bitcoin escrow services, (2) bitcoin mining, and (3) blockchain software development.

For more information see <https://en.wikipedia.org/wiki/Bitcoin#Mining>.

B. Date and State (or Jurisdiction) of Incorporation:

April 4, 1997; Nevada

C. the issuer's primary and secondary SIC Codes;

2836 - Biological products, except diagnostic

D. the issuer's fiscal year end date;

12/31

E. principal products or services, and their markets;

The principal products and services are the mining of bitcoins, proving escrow services for buyers and sellers of bitcoins, and the development and sale of blockchain software. The market for these services and products is Worldwide, and sold and marketed on the Internet.

For more information see <https://en.wikipedia.org/wiki/Bitcoin#Mining>.

## **7) Describe the Issuer's Facilities**

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The issuers facilities are leased on a monthly basis. They consist of executive office suites and remote mail drop centers in several states. Principally in Michigan, Florida and Colorado. Our operations are Internet based and these facilities suit our needs. The cost is minimal and fluctuates depending on the services required, and range in total from \$350. to \$500 monthly.

## **8) Officers, Directors, and Control Persons**

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

<u>Name and Position</u>	<u>Shares of Common Stock</u>	<u>Percentage of Class (Common)</u>	<u>Shares of Series A Preferred Stock</u>	<u>Perce ntage of Class A Preferr ed</u>	<u>Shares of Series B Preferred Stock</u>	<u>Percent age of Class B Preferre d</u>
James Jordhamo, Jr., Acting Director/Custodian	50,000,000.	74.7%	5,000,000.	53.2%	5,000,000.	78.5%

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

<u>Name and Position</u>	<u>Shares of Common Stock</u>	<u>Percentage of Class (Common)</u>	<u>Shares of Series A Preferred Stock</u>	<u>Perce ntage of Class A Preferr</u>	<u>Shares of Series B Preferred Stock</u>	<u>Percent age of Class B Preferre</u>
--------------------------	---------------------------------------	---	---	---	---	--

				<u>ed</u>		<u>d</u>
Hamo Enterprises, Inc. c/o James Jordhamo, Jr., President 2885 Sanford Ave SW, 34538 Grandville, MI 49418	50,000,000.	74.7%	5,000,000.	53.2%	5,000,000.	78.5%

## 9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

### Legal Counsel

Name: Benjamin L. Bunker, Esq.  
The Bunker Law Group, PLLC  
3753 Howard Hughes Parkway, Suite 200  
Las Vegas, Nevada 89169  
[benbunker@bunkerlawgroup.com](mailto:benbunker@bunkerlawgroup.com)  
T (702) 784-5990  
F 888.460.8609

### Accountant or Auditor

Name: Sanjay Aurora.  
Firm: Finance & Technology Consultants, Inc.  
Address 1: \_\_\_\_\_  
Address 2: West Palm Beach, FL \_\_\_\_\_  
Phone: 561-282-6744 \_\_\_\_\_  
Email: [sanjay@ft-consultants.com](mailto:sanjay@ft-consultants.com)

### Investor Relations Consultant

Name: None  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

Name: None  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

## 10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, James Jordhamo, Jr. certify that:

1. I have reviewed these 2014 and 2015 Annual Disclosure Statements of Tulip Biomed, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.


February 3, 2016 [Date]

/s/ James Jordhamo, Jr., CEO  
[CEO's Signature]

/s/ James Jordhamo, Jr., CFO [CFO's Signature]  
(Digital Signatures should appear as "/s/ [OFFICER NAME]")

CEO/CFO [Title]

# SECRETARY OF STATE



## NEVADA STATE BUSINESS LICENSE

**TULIP BIOMED, INC.**

Nevada Business Identification # NV19971143068

**Expiration Date: April 30, 2016**

In accordance with Title 7 of Nevada Revised Statutes, pursuant to proper application duly filed and payment of appropriate prescribed fees, the above named is hereby granted a Nevada State Business License for business activities conducted within the State of Nevada.

Valid until the expiration date listed unless suspended, revoked or cancelled in accordance with the provisions in Nevada Revised Statutes. License is not transferable and is not in lieu of any local business license, permit or registration.



IN WITNESS WHEREOF, I have hereunto set my hand and affixed the Great Seal of State, at my office on January 6, 2016

*Barbara K. Cegavske*

BARBARA K. CEGAVSKE  
Secretary of State

***You may verify this license at [www.nvsos.gov](http://www.nvsos.gov) under the Nevada Business Search.***

License must be cancelled on or before its expiration date if business activity ceases.  
Failure to do so will result in late fees or penalties which by law cannot be waived.



NOTES TO FINANCIALS FOR PERIODS  
ENDING DECEMBER 31, 2014 & DECEMBER 31, 2015

**Note 1 - Organization and Summary of Significant Accounting Policies**  
**Forward Looking Statements**

Some of the statements contained in this information statement that are not historical facts are "forward-looking statements" which can be identified by the use of terminology such as "estimates," "projects," "plans," "believes," "expects," "anticipates," "intends," or the negative or other variations, or by discussions of strategy that involve risks and uncertainties. We urge you to be cautious of the forward-looking statements, that such statements, which are contained in this prospectus, reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors affecting our operations, market growth, services, products and licenses. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of the risks we face, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, our performance or achievements, or industry results, to differ materially from those contemplated by such forward-looking statements include without limitation:

- Our ability to attract and retain management, and to integrate and maintain technical information and management information systems;
- Our ability to raise capital when needed and on acceptable terms and conditions;
- The intensity of competition; and
- General economic conditions.

All written and oral forward-looking statements made in connection with this prospectus that are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements.

During the next twelve months, the Company's plans to expand its business into other countries. The Company plans to finance its growth through traditional bank financing sources as well as additional potential debt and equity private placements. To that end, the Company may attempt to raise money in a private placement of its shares of Common Stock, but has not yet commenced this initiative. There can be no assurance that financing sufficient to enable us to expand and grow our business will be available to us in the future. The failure to obtain future financing or to produce levels of revenue to meet our financial needs could result in our inability to operate, grow and expand our business.

**Off-Balance Sheet Arrangements**

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

**Organization of Business**

Tulip Biomed, Inc. (the "Company") was incorporated in Nevada in 1997 under the name "JLL Miami Enterprises, Inc." until January 2002 when its name was changed to "BMX Holdings, Inc.", until February 2003 when its name was changed to "Direct Music Group, Inc." until April 2004 when

its name was changed to "Cell Bio-Systems, Inc.", until June 2006 when its name was changed to Tulip Biomed, Inc. On December 21, 2015, under Nevada NRS 78.347 an Order of Appointment of Custodianship was entered appointing Hamo Enterprises, Inc. to comply with NRS 78.180 to reinstate the Company with the Nevada Secretary of State, etc. and in accordance with the statute. The issuer's business operations are each Internet based to the consumer and consist of three separate streams, as follows: (1) bitcoin escrow services, (2) bitcoin mining, and (3) blockchain software development. The principal products and services are the mining of bitcoins, providing escrow services for buyers and sellers of bitcoins, and the development and sale of blockchain software. The market for these services and products is Worldwide, and sold and marketed on the Internet. On January 6, 2016, the Company reinstated its business license with the State of Nevada. A copy is attached.

### ***Amendment of Articles***

For the period ending December 31, 2014 and December 31, 2015, no Amendments to the Articles were done.

### **Principles of Consolidation**

The accompanying consolidated financial statements include all applicable accounts and subsidiaries of the Company. All significant inter-company transactions and balances have been eliminated in consolidation.

### **Basis of Presentation**

The accompany unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America. Certain information and note disclosure normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year.

### **Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reporting amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods. Management makes these estimates using the best information available at the time the estimates are made; however, actual results could differ materially from these estimates.

### **Net Loss per Share**

ASC 260, "Earnings per Share," requires dual presentation of basic and diluted earnings or loss per share ("EPS") for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution; diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Basic loss per share is computed by dividing net loss applicable to common shareholders by the weighted average

number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if dilutive securities and other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company, unless the effect is to reduce a loss or increase earnings per share. The Company has outstanding common stock purchase warrants; however, inclusion of the warrants in the calculation of diluted loss per share would be anti-dilutive. Therefore, diluted loss per share is equivalent to basic loss per share.

### **Cash and Cash Equivalents**

Cash and cash equivalents include cash on hand and cash in deposits and all highly liquid debt instruments with an original maturity of three months or less.

### **Revenue Recognition**

The Company recognizes revenue in accordance with the provisions of Staff Accounting Bulletin (“SAB”) 104. Sales and service revenue is recognized at the date of shipment, or completion of services rendered, to a customer when a formal arrangement exists, the price is fixed or determinable, the delivery or service is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all the relevant criteria for revenue recognition are recorded as customer deposits.

### **Accounts Receivable and Allowance for Doubtful Accounts**

Trade receivables are non-interest bearing, uncollateralized customer obligations and are stated at the amounts billed to customers. The preparation of financial statements requires management to make estimates and assumptions relating to the collectability of accounts receivable. Management specifically analyzes historical bad debts, customer credit worthiness, current economic trends and changes in customer payment terms when evaluating the adequacy of the allowance for doubtful accounts.

### **Property and Equipment**

Property and equipment are stated at cost less accumulated depreciation and amortization. The Company computes depreciation and amortization using the straight-line method over the estimated useful lives of the assets acquired as follows:

Building	39 years
Computer equipment	3-5 years
Furniture and fixtures	5-7 years
Machinery and equipment	5-10 years
Trucks and automobiles	5 years

When assets are retired or otherwise disposed of, the cost and related accumulated depreciation or amortization are removed from the accounts, and any resulting gain or loss is reflected in the consolidated statements of operations. Repairs and maintenance that do not extend the useful lives of the related assets are expensed as incurred.

### **Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Management plans to raise additional proceeds from debt and equity transactions and to

continue to increase its sales and marketing activities. There is no guarantee, however, that management will be able to secure sufficient financing to sustain the operations of the Company or that operations will become self-sustaining. In the absence of one of those accomplishments, the Company would likely be forced to liquidate. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event the Company cannot continue in existence.

### **Business Combinations**

Acquisitions of businesses are accounted for using the purchase method of accounting, and the financial statements include the results of the acquired operations from the respective dates they were acquired. The purchase price of the acquired entities is allocated to the net assets acquired and liabilities assumed based on the estimated fair value at the dates of acquisition, with any excess of cost over the fair value of net assets acquired, including intangibles, recognized as goodwill. The balances included in the consolidated balance sheets related to recent acquisitions are based upon preliminary information and are subject to change when final asset and liability valuations are obtained. Material changes to the preliminary allocations are not anticipated by management.

### **Fair Value Measurements**

The FASB's Accounting Standards Codification defines fair value as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction between market participants and requires that assets and liabilities carried at fair value are classified and disclosed in the following three categories:

Level 1 – Quoted prices for identical instruments in active markets.

Level 2 – Quoted prices for similar instruments in active or inactive markets and valuations derived from models where all significant inputs are observable in active markets.

Level 3 – Valuations derived from valuation techniques in which one or more significant inputs are unobservable in any market.

### **Fair Value of Financial Instruments**

The carrying values of cash, prepaid expenses, accounts payable and accrued expenses approximate their fair values due to their short term maturities. The carrying values of the Company's notes payable approximate their fair values based upon a comparison of the interest rate and terms of such debt given the level of risk to the rates and terms of similar debt currently available to the Company in the marketplace.

### **Recent Accounting Pronouncements**

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying condensed consolidated financial statements.

### **Note 2 - Stockholders' Equity**

For the periods ending December 31, 2014 and December 31, 2015, the Company was authorized to issue:

500,000,000 shares of \$.001 par value Common stock;

100,000,000 shares of \$0.001 per value Series A Preferred stock; and

20,000,000 shares of \$0.001 par value Series B Convertible Preferred stock.

Dividends may be paid on outstanding shares as declared by the Board of Directors.

Shares of Series "A" Preferred Stock enjoy dividend and liquidation preferences, are entitled to vote, and are convertible into one share of Common Stock at an exercise price of \$.001 per share at the earlier to occur of (i) a firmly underwritten public offering covering the primary sale of Common Stock, (ii) a vote or written consent of holders of at least a simple majority of the Series "A" Preferred Stock then outstanding, voting as a class, or (iii) December 31, 2006.

Shares of Series "B" Preferred Stock are convertible into one share of Common Stock only at the express authorization of the Company to convert.

### **Note 3 – Business Combination**

For the period ending December 31, 2014 and December 31, 2015, the Company did not engage in any business combinations or mergers. No shares have been sold in any private placements for the period ending December 31, 2014 and December 31, 2015.

### **Note 4 - Income Taxes**

The Company's net deferred tax assets consist primarily of net operating loss carry-forwards. These net operating loss carry-forwards expire over various years through 2029. The net operating loss carry forwards may be limited under the Change of Control provisions of the Internal Revenue Code section 382. There is no income tax provision for the year due to the change in valuation allowance. The difference between the effective rate and the statutory rate is the result of the change in the valuation allowance.

### **Note 5 - Going Concern**

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. For the annual period ending December 31, 2014, the Company had incurred a net \$21,848.47 loss. For the annual period ending December 31, 2015, the Company had incurred a net loss of \$71,929.92. The ability of the Company to continue as a going concern is dependent on raising capital to fund its business plan and ultimately to attain profitable operations. Accordingly, these factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

### **Note 6—Related Party Transactions**

For the annual periods ending December 31, 2014 and December 31, 2015, the Company did not engage in any related party transactions.

### **Note 7 - Lawsuits**

The Company is named as a party to a lawsuit as discussed above and is currently under an appointment of custodianship that is anticipated to be concluded and dismissed within the next twenty (20) days. This lawsuit was filed in November 2015 and an Order of appointment of custodianship was entered on December 21, 2015.

### **Note 8 - Notes Payable**

None.

### **Note 9- Convertible Notes Payable**

None.

#### **Note 10 – Subsequent Events**

On January 6, 2016, the Company reinstated its business license with the State of Nevada. A copy is attached.

In early January, January 11, 2016 was established as the record date for a shareholder meeting with Broadridge, and all other requirements thereto have been carried out.

On January 11, 2016, for consideration of certain advancements of funds and services rendered to the Company, the Company issued Hamo Enterprises, Inc. fifty million common shares, five million series a preferred and five million series b preferred shares. All of these shares are restricted and control person shares.

On January 25, 2016 the Company was named in two separate lawsuits by claimants for monies advanced and owed, and for invoiced services rendered for operations to the Company. The Company has agreed to settlement, and awaits approval of the terms by the Court whereby shares of stock will be issued in full settlement of both claims.

On January 31, 2016, pursuant to agreement, the Company issued one hundred and fifty thousand (150,000) restricted shares of the common stock to the principal of Finance & Technology Consultants, Inc. for accounting services rendered in preparation of the 2014 & 2015 Annual Reports for the Company.

On January 31, 2016, pursuant to agreement, the Company issued Two Million and Five Hundred (2,500,000.) restricted shares of the common stock and paid \$2,500. to TST Advisors LLC, for content management, E-Commerce Solutions, affiliate Consulting, Third party payment options, Analytics, Search Engine Optimization, Custom WordPress Development, Custom Web Development, custom logo design, custom landing pages, custom web site design, web development, social networks, web site consulting, corporate identity package, web site management, and web site hosting services.

---

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Consolidated Balance Sheet**

as at	Dec 31, 2014	Dec 31, 2015
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>	<b>\$</b>	
Cash	0.00	0.00
Accounts Receivable	0.00	0.00
Current Assets	0.00	0.00
<b>TOTAL CURRENT ASSETS</b>	<b>0.00</b>	<b>0.00</b>
<b>PROPERTY AND EQUIPMENT</b>		
Machinery, Auto and equipment	0.00	0.00
Less: Accumulated Deprecations	0.00	0.00
<b>Property &amp; Equipment - NET</b>	<b>0.00</b>	<b>0.00</b>
<b>TOTAL ASSETS</b>	<b>0.00</b>	<b>0.00</b>
<b>LIABILITIES AND STOCKHOLDER EQUITY (DEFICIT)</b>		
<b>CURRENT LIABILITIES</b>	<b>\$</b>	
Accounts Payable and Accrued Expenses	21,848.47	93,778.39
<b>TOTAL CURRENT LIABILITIES</b>	<b>21,848.47</b>	<b>93,778.39</b>
<b>STOCKHOLER EQUITY</b>		
Common Stock par value \$.001 per share 500,000,000 shares authorized 16,917,051 shares issued and outstanding at end of each year	16,917.05	16,917.05
PREFERRED "A" shares par value \$.001 per share 100,000,000 shares authorized 1,366,666 shares issued and outstanding at end of each year	1,366.67	1,366.67
PREFERRED "B" shares par value \$.001 per share 20,000,000 shares authorized 4,390,362 shares issued and outstanding at end of each year	4,390.36	4,390.36
Accumulated Deficit	(44,522.55)	(116,452.47)
<b>TOTAL STOCKHOLDER EQUITY (DEFICIT)</b>	<b>(21,848.47)</b>	<b>(93,778.39)</b>
<b>TOTAL LAIBILITIES AND SHAREHOLDER EQUITY (DEFICIT)</b>	<b>0.00</b>	<b>0.00</b>

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Consolidated Statement of Operations**

as at	Dec 31, 2014	Dec 31, 2015
SALES	\$ 0.00	0.00
SERVICE	0.00	0.00
OTHER INCOME	0.00	0.00
<b>GROSS SALES</b>	<b>0.00</b>	<b>0.00</b>
<b>OPERATING EXPENSES</b>		
General & Administrative expenses	21,848.47	71,929.92
Amortization	0.00	0.00
Deprecation	0.00	0.00
Accrued Interest	0.00	0.00
<b>TOTAL EXPENSES</b>	<b>21,848.47</b>	<b>71,929.92</b>
Income before provision for Income taxes	(21,848.47)	(71,929.92)
NOL USED (if any)	0.00	0.00
Provision for Income Taxes	0.00	0.00
<b>NET INCOME (LOSS)</b>	<b>(21,848.47)</b>	<b>(71,929.92)</b>

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*



**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Consolidated Statement of Cash flows**

as at	Dec 31, 2014	Dec 31, 2015
Net Income (Loss)	\$ (21,848.47)	(71,929.92)
<i><b>Adjustment to reconcile Net Income</b></i>		
Accounts Payable	21,828.47	71,929.92
Accrued Interest	0.00	0.00
Deprecations and Amortization	0.00	0.00
<b>Net cash provided by Operating Activities</b>	<b>0.00</b>	<b>0.00</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Loans and Other Notes	0.00	0.00
<b>Net cash provided by Investing Activities</b>	<b>0.00</b>	<b>0.00</b>
<b>NET CASH INCREASE FOR THE PERIOD</b>	<b>0.00</b>	<b>0.00</b>
<b>CASH AT THE BEGINNING OF PERIOD</b>	<b>0.00</b>	<b>0.00</b>
<b>CASH AT THE END OF THE PERIOD</b>	<b>0.00</b>	<b>0.00</b>

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Consolidated Statement of Changes in Stockholders Equity**

	Common Stock			Accumulated Deficit	
	Shares	Amount	Capital	Stage	Total
<b>December 31, 2014</b>					
Common stock issued for cash at \$.000001 per share	16,917,051	\$16,917.05	\$0.00	(44,522.55)	(27,605.50)
Preferred “A” stock issued for cash at \$.000001 per share	1,366,666	\$1,366.67	\$0.00	\$0.00	\$1,366.67
Preferred “B” stock issued for cash at \$.000001 per share	4,390,362	\$4,390.36	\$0.00	\$0.00	\$4,390.36
<b>December 31, 2015</b>					
Common stock issued for cash at \$.000001 per share	16,917,051	\$16,917.05	\$0.00	(116,452.47)	(99,535.42)
Preferred “A” stock issued for cash at \$.000001 per share	1,366,666	\$1,366.67	\$0.00	\$0.00	\$1,366.67
Preferred “B” stock issued for cash at \$.000001 per share	4,390,362	\$4,390.36	\$0.00	\$0.00	\$4,390.36

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Balance Sheet**

**as at**

**Dec 31, 2014**

**ASSETS**

**CURRENT ASSETS**

\$

Cash 0.00

Accounts Receivable 0.00

Current Assets 0.00

**TOTAL CURRENT ASSETS 0.00**

**PROPERTY AND EQUIPMENT**

Machinery, Auto and equipment 0.00

Less: Accumulated Deprecations 0.00

**Property & Equipment - NET 0.00**

**TOTAL ASSETS 0.00**

**LIABILITIES AND STOCKHOLDER EQUITY (DEFICIT)**

**CURRENT LIABILITIES**

\$

Accounts Payable and Accrued Expenses 21,848.47

**TOTAL CURRENT LIABILITIES 21,848.47**

**STOCKHOLDER EQUITY**

Common Stock par value \$.001 per share 16,917.05  
500,000,000 shares authorized  
16,917,051 shares issued and outstanding at end of each year

PREFERRED "A" shares par value \$.001 per share  
100,000,000 shares authorized  
1,366,666 shares issued and outstanding at end of each year 1,366.67

PREFERRED "B" shares par value \$.001 per share  
20,000,000 shares authorized  
4,390,362 shares issued and outstanding at end of each year 4,390.36

Accumulated Deficit (44,522.55)

**TOTAL STOCKHOLDER EQUITY (DEFICIT) (21,848.47)**

**TOTAL LAIBILITIES AND SHAREHOLDER EQUITY (DEFICIT) 0.00**

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Statement of Operations**

<b>as at</b>		<b>Dec 31, 2014</b>
SALES	\$	0.00
SERVICE		0.00
OTHER INCOME		0.00
<b>GROSS SALES</b>		<b>0.00</b>
<b>OPERATING EXPENSES</b>		
General & Administrative expenses		21,848.47
Amortization		0.00
Deprecation		0.00
Accrued Interest		0.00
<b>TOTAL EXPENSES</b>		<b>21,848.47</b>
Income before provision for Income taxes		(21,848.47)
NOL USED (if any)		0.00
Provision for Income Taxes		0.00
<b>NET INCOME (LOSS)</b>		<b>(21,848.47)</b>

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Statement of Cash flows**

**as at**

**Dec 31, 2014**

Net Income (Loss)	\$	(21,848.47)
<i>Adjustment to reconcile Net Income</i>		
Accounts Payable		21,828.47
Accrued Interest		0.00
Deprecations and Amortization		0.00
<hr/>		
Net cash provided by Operating Activities		<b>0.00</b>
<hr/>		
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Loans and Other Notes		0.00
<hr/>		
Net cash provided by Investing Activities		0.00
<hr/>		
NET CASH INCREASE FOR THE PERIOD		<b>0.00</b>
<hr/>		
CASH AT THE BEGINNING OF PERIOD		<b>0.00</b>
<hr/>		
CASH AT THE END OF THE PERIOD		<b>0.00</b>

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Statement of Changes in Stockholders Equity**

	Common Stock			Accumulated Deficit	
	Shares	Amount	Capital	Stage	Total
<b>December 31, 2014</b>					
Common stock issued for cash at \$.000001 per share	16,917,051	\$16,917.05	\$0.00	(44,522.55)	(27,605.50)
Preferred “A” stock issued for cash at \$.000001 per share	1,366,666	\$1,366.67	\$0.00	\$0.00	\$1,366.67
Preferred “B” stock issued for cash at \$.000001 per share	4,390,362	\$4,390.36	\$0.00	\$0.00	\$4,390.36

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Consolidated Balance Sheet**

as at

Dec 31, 2015

ASSETS	
<b>CURRENT ASSETS</b>	\$
Cash	0.00
Accounts Receivable	0.00
Current Assets	0.00
<b>TOTAL CURRENT ASSETS</b>	<b>0.00</b>
<b>PROPERTY AND EQUIPMENT</b>	
Machinery, Auto and equipment	0.00
Less: Accumulated Deprecations	0.00
<b>Property &amp; Equipment - NET</b>	<b>0.00</b>
<b>TOTAL ASSETS</b>	<b>0.00</b>
LIABILITIES AND STOCKHOLDER EQUITY (DEFICIT)	
<b>CURRENT LIABILITIES</b>	\$
Accounts Payable and Accrued Expenses	93,778.39
<b>TOTAL CURRENT LIABILITIES</b>	<b>93,778.39</b>
<b>STOCKHOLDER EQUITY</b>	
Common Stock par value \$.001 per share	16,917.05
500,000,000 shares authorized	
16,917,051 shares issued and outstanding at end of each year	
PREFERRED "A" shares par value \$.001 per share	
100,000,000 shares authorized	
1,366,666 shares issued and outstanding at end of each year	1,366.67
PREFERRED "B" shares par value \$.001 per share	
20,000,000 shares authorized	
4,390,362 shares issued and outstanding at end of each year	4,390.36
Accumulated Deficit	(116,452.47)
<b>TOTAL STOCKHOLDER EQUITY (DEFICIT)</b>	<b>(93,778.39)</b>
<b>TOTAL LAIBILITIES AND SHAREHOLDER EQUITY (DEFICIT)</b>	<b>0.00</b>

(UNAUDITED)

*The accompanying notes are an integral part of the consolidated financial statements*

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Consolidated Statement of Operations**

as at

Dec 31, 2015

SALES	\$	0.00
SERVICE		0.00
OTHER INCOME		0.00
<b>GROSS SALES</b>		<b>0.00</b>
<b>OPERATING EXPENSES</b>		
General & Administrative expenses		71,929.92
Amortization		0.00
Deprecation		0.00
Accrued Interest		0.00
<b>TOTAL EXPENSES</b>		<b>71,929.92</b>
Income before provision for Income taxes		(71,929.92)
<b>NOL USED (if any)</b>		<b>0.00</b>
<b>Provision for Income Taxes</b>		<b>0.00</b>
<b>NET INCOME (LOSS)</b>		<b>(71,929.92)</b>

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*



**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Consolidated Statement of Cash flows**

as at

Dec 31, 2015

Net Income (Loss)	\$	(71,929.92)
<b><i>Adjustment to reconcile Net Income</i></b>		
Accounts Payable		71,929.92
Accrued Interest		0.00
Deprecations and Amortization		0.00
<hr/>		
Net cash provided by Operating Activities		<b>0.00</b>
<hr/>		
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Loans and Other Notes		0.00
<hr/>		
Net cash provided by Investing Activities		0.00
<hr/>		
NET CASH INCREASE FOR THE PERIOD		<b>0.00</b>
<hr/>		
CASH AT THE BEGINNING OF PERIOD		<b>0.00</b>
<hr/>		
CASH AT THE END OF THE PERIOD		<b>0.00</b>

**(UNAUDITED)**

***The accompanying notes are an integral part of the consolidated financial statements***

**TULIP BIOMED INC.**  
**CONDENSED FINANCIALS – CONDENSED & YEARLY**

**Condensed Consolidated Statement of Changes in Stockholders Equity**

	Common Stock			Accumulated Deficit	
	Shares	Amount	Capital	Stage	Total
<b>December 31, 2015</b>					
Common stock issued for cash at \$.000001 per share	16,917,051	\$16,917.05	\$0.00	(116,452.47)	(99,535.42)
Preferred “A” stock issued for cash at \$.000001 per share	1,366,666	\$1,366.67	\$0.00	\$0.00	\$1,366.67
Preferred “B” stock issued for cash at \$.000001 per share	4,390,362	\$4,390.36	\$0.00	\$0.00	\$4,390.36

**(UNAUDITED)**

*The accompanying notes are an integral part of the consolidated financial statements*